What the Prolia TV commercial - Headed in the Right Direction is about.
Prolia is a prescription drug used for the treatment of osteoporosis in postmenopausal women. In their latest TV spot titled 'Headed in the Right Direction,' the makers of Prolia aim to showcase the benefits of the drug and how it can positively impact the lives of women struggling with osteoporosis.
The commercial features a woman who is shown walking on a rocky terrain, symbolizing the challenges of living with osteoporosis. However, as she continues to walk, the terrain gradually transforms into a smoother path, signifying the progress she has made in managing her condition with Prolia.
Throughout the commercial, the narrator highlights the positive effects of Prolia, such as reducing the risk of fractures and increasing bone density. The ad also emphasizes the convenience of the drug therapy, which only requires an injection every six months compared to daily medication.
The overall message of the 'Headed in the Right Direction' TV spot is that Prolia can empower postmenopausal women to live their life to the fullest without the fear of debilitating fractures caused by osteoporosis. The ad concludes with a call-to-action encouraging viewers to speak to their healthcare provider to see if Prolia is the right treatment option for them.
Overall, the Prolia TV spot is an effective way to create awareness about the drug and highlight its benefits to potential patients. The commercial's powerful visuals and relatable message make it highly engaging, while its call-to-action ensures that viewers are taking proactive steps towards a healthier future.
Prolia TV commercial - Headed in the Right Direction produced for
Prolia
was first shown on television on September 9, 2018.
Frequently Asked Questions about prolia tv spot, 'headed in the right direction'
"What I'm working on with my doctor is a plan that includes exercising, eating right and taking a medicine called Prolia® along with calcium and vitamin D," said Danner. "Every woman is different, and I encourage women to work with their doctors on a plan that is right for them."
Fosamax is usually the first-choice option for osteoporosis. But Prolia may be preferred in people with very high fracture risk. The most common side effects of Boniva and Fosamax are gastrointestinal symptoms like acid reflux, nausea, and diarrhea.
Specifically, Prolia works by blocking a protein called RANK. The drug attaches to the RANK protein and helps prevent osteoclasts from breaking down bone. Over time, Prolia helps to improve the density and strength of your bones by slowing bone loss. This lowers your risk for bone fractures.
In this study, the females' bone mineral density (BMD) was measured. (BMD is a measurement that shows how strong your bones are.) After 12 months of treatment, BMD measured at the hip was increased by 3.5% in females taking Prolia.
Specifically, Prolia works by blocking a protein called RANK. The drug attaches to the RANK protein and helps prevent osteoclasts from breaking down bone. Over time, Prolia helps to improve the density and strength of your bones by slowing bone loss. This lowers your risk for bone fractures.
(BMD is a measurement that shows how strong your bones are.) After 12 months of treatment, BMD measured at the hip was increased by 3.5% in females taking Prolia.
Official answer. Yes, Prolia (denosumab) does increase bone density.
It is important that you should NOT stop Prolia without discussing this with your healthcare professional. Stopping Prolia can cause an increase in the number of multiple vertebral fractures often within a year of stopping.
(These drugs are made from immune system cells.) Prolia works by decreasing bone breakdown in your body. This leads to reduced bone loss and helps to treat osteoporosis. Prolia is given by healthcare professionals as an injection under your skin (called a subcutaneous injection).
Official answer. Yes, Prolia (denosumab) does increase bone density. Research has shown that Prolia significantly increased bone mineral density (BMD) by 8.8% at the lumbar spine, 6.4% at the total hip, and 5.2% at the femoral neck in trials that measured BMD after three years of treatment with Prolia.
Yes, Prolia (denosumab) does increase bone density. Research has shown that Prolia significantly increased bone mineral density (BMD) by 8.8% at the lumbar spine, 6.4% at the total hip, and 5.2% at the femoral neck in trials that measured BMD after three years of treatment with Prolia.
by Drugs.com
Yes, Prolia (denosumab) does increase bone density. Research has shown that Prolia significantly increased bone mineral density (BMD) by 8.8% at the lumbar spine, 6.4% at the total hip, and 5.2% at the femoral neck in trials that measured BMD after three years of treatment with Prolia.